Opendata, web and dolomites

RESCUER SIGNED

RESISTANCE UNDER COMBINATORIAL TREATMENT IN ER+ AND ER- BREAST CANCER.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RESCUER project word cloud

Explore the words cloud of the RESCUER project. It provides you a very rough idea of what is the project "RESCUER" about.

indication    tried    integrate    frameworks    tumor    computer    exploring    drug    benefit    subtypes    responders    samples    curative    omics    solid    heterogeneity    animal    gather    endowed    degree    approved    combinations    network    patients    classified    first    model    drugs    despite    mechanisms    few    silico    trials    xenograft    actually    thin    death    ethics    ongoing    therapy    worldwide    everyone    patient    combinatorial    arbitrary    overreaching    combination    algorithms    ethical    signatures    clinical    breast    discover    vivo    effectiveness    predict    physiological    stratification    strata    individual    efficient    optimization    framework    women    vs    tested    sub    bc    alternative    treatment    probability    omic    models    longitudinal    computational    personalized    purpose    multidimensional    resistance    therapies    molecular    newly    cancer    organ    data    administering    cellular    ex    aspects    biological    combine   

Project "RESCUER" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITETET I OSLO 

Organization address
address: PROBLEMVEIEN 5-7
city: OSLO
postcode: 313
website: www.uio.no

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 6˙283˙250 €
 EC max contribution 6˙000˙000 € (95%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITETET I OSLO NO (OSLO) coordinator 933˙543.00
2    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) participant 946˙443.00
3    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 935˙625.00
4    UNIVERSITAT DE BARCELONA ES (BARCELONA) participant 466˙337.00
5    VIB BE (ZWIJNAARDE - GENT) participant 464˙375.00
6    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 424˙781.00
7    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 400˙000.00
8    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 389˙012.00
9    INTERDISCIPLINARY CENTER (IDC) HERZLIYA IL (HERZLIYA) participant 371˙875.00
10    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 273˙000.00
11    UNIVERSITATSKLINIKUM ERLANGEN DE (ERLANGEN) participant 245˙712.00
12    INSTITUT FUR FRAUENGESUNDHEIT GMBH DE (ERLANGEN) participant 141˙293.00
13    RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY US (NEW BRUNSWICK) participant 8˙000.00
14    NANTOMICS LLC US (DOVER) participant 0.00
15    NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU NO (TRONDHEIM) participant 0.00

Map

 Project objective

Breast Cancer (BC) is the first cause of cancer-related death in women worldwide. Breast cancer is classified into well-recognized molecular subtypes. Despite solid pre-clinical evidence, only some patients benefit from administering drug combinations, an indication that patient and tumor heterogeneity is still present in the current stratification. Out of the numerous possible combinations of approved drugs, only a few have been actually tried, and the choice of tested combinations has been to some degree arbitrary. This proposal seeks to develop new approaches and identify mechanisms of treatment resistance at systems level, exploring how the effectiveness of specific targeted therapies applied in different clinical trials is affected by patient- and tumor-specific conditions. For this purpose, the project will gather and integrate longitudinal multidimensional data from ongoing clinical trials and newly generated --omics using systems approaches, which combine sub-cellular/cellular and/or organ level in-silico models and network analysis to build computational frameworks able to discover molecular signatures of resistance and predict patient response to combinatorial therapies. We aim to identify the physiological characteristics of non-responders vs. responders from existing and newly generated multi-omic data and biological samples from in-vivo and ex-vivo clinical studies of specific subtypes of BC patients treated with combination therapy. This new knowledge will be used to investigate the curative potential of new personalized drugs combinations. The overreaching goal is to develop computer “xenograft model” as a cost-efficient and better alternative in terms of ethics, availability to everyone, and animal use. The framework will include optimization algorithms to identify combinations of approved drugs with a high probability to work on individual or thin strata of patients. The project is endowed with a “legal” framework addressing ethical aspects

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESCUER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESCUER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More  

DC-ren (2020)

Drug combinations for rewriting trajectories of renal pathologies in type II diabetes (DC-ren)

Read More  

DECISION (2020)

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Read More